Lani
10-11-2006, 04:16 AM
Histone deacetylase inhibitor approved-- a few days ago I read a new multitargetted monoclonal antibody was approved, but was too busy to post.
Will try to find that too!:
\
Merck Says FDA Approves Zolinza for Lymphoma
Information from Industry
GEMZAR® (gemcitabine HCI) - A new first-line combination therapy demonstrated superior TTP and RR compared to paclitaxel alone in a phase III metastatic breast cancer trial.
Review clinical data and read Important Safety Considerations.
Other Product InfoSites »
CHICAGO (Reuters) Oct 09 - Merck & Co. Inc. on Monday said U.S. regulators approved the drugmaker's new treatment for a form of non-Hodgkin's lymphoma in patients who have failed other therapies.
Merck said the U.S. Food and Drug Administration approved the treatment, called Zolinza, for patients with cutaneous T-cell lymphoma for those with progressive, persistent or recurrent forms of the disease.
Zolinza, also known as vorinostat or suberoylanilide hydroxamic acid (SAHA), is in a new class of anti-cancer therapies called histone deacetylase (HDAC) inhibitors.
Histone deacetylation is thought to be a mechanism for silencing some tumour suppressor genes and other genes responsible for cell cycle progression, cell proliferation, apoptosis and differentiation.
I report these as they have been shown to be helpful in preclinical work in breast cancer , may have had clinical trials initiated and would now be available for off-label use.
Sorry just arrived back with jetlag(9 hours time difference plus almost 24 hours of travelling) prevents more comments,info!
Will try to find that too!:
\
Merck Says FDA Approves Zolinza for Lymphoma
Information from Industry
GEMZAR® (gemcitabine HCI) - A new first-line combination therapy demonstrated superior TTP and RR compared to paclitaxel alone in a phase III metastatic breast cancer trial.
Review clinical data and read Important Safety Considerations.
Other Product InfoSites »
CHICAGO (Reuters) Oct 09 - Merck & Co. Inc. on Monday said U.S. regulators approved the drugmaker's new treatment for a form of non-Hodgkin's lymphoma in patients who have failed other therapies.
Merck said the U.S. Food and Drug Administration approved the treatment, called Zolinza, for patients with cutaneous T-cell lymphoma for those with progressive, persistent or recurrent forms of the disease.
Zolinza, also known as vorinostat or suberoylanilide hydroxamic acid (SAHA), is in a new class of anti-cancer therapies called histone deacetylase (HDAC) inhibitors.
Histone deacetylation is thought to be a mechanism for silencing some tumour suppressor genes and other genes responsible for cell cycle progression, cell proliferation, apoptosis and differentiation.
I report these as they have been shown to be helpful in preclinical work in breast cancer , may have had clinical trials initiated and would now be available for off-label use.
Sorry just arrived back with jetlag(9 hours time difference plus almost 24 hours of travelling) prevents more comments,info!